HCA
TARS icon

Harbor Capital Advisors’s Tarsus Pharmaceuticals TARS Stock Holding History

Harbor Capital Advisors’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.86M Buy
29,612
+329
+1% +$21K 0.13% 241
2026
Q1 		$2.05M Buy
29,283
+7,561
+35% +$528K 0.17% 177
2025
Q4 		$1.78M Buy
21,722
+6,134
+39% +$458K 0.14% 198
2025
Q3 		$926K Sell
15,588
-8,679
-36% -$427K 0.07% 338
2025
Q2 		$983K Buy
24,267
+3,499
+17% +$157K 0.04% 437
2025
Q1 		$1.07M Sell
20,768
-1,345
-6% -$66.5K 0.05% 421
2024
Q4 		$1.22M Buy
22,113
+4,008
+22% +$182K 0.05% 414
2024
Q3 		$595K Buy
18,105
+6,612
+58% +$186K 0.03% 545
2024
Q2 		$312K Sell
11,493
-127
-1% -$4.27K 0.02% 601
2024
Q1 		$422K Buy
+11,620
New +$342K 0.06% 441

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Harbor Capital Advisors's TARS Position: Q2 2026 in Review

Harbor Capital Advisors increased its Tarsus Pharmaceuticals (TARS) stake by 1.1% in Q2 2026, buying an estimated $21K and bringing the position to 29,612 shares worth $1.86M. The position accounts for 0.13% of the portfolio, ranked #241.

Harbor Capital Advisors first reported a position in TARS in Q1 2024 and has held it in 10 quarters since. The position peaked at $2.05M in Q1 2026. 256 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Harbor Capital Advisors held 29,612 shares of Tarsus Pharmaceuticals worth $1.86M as of Q2 2026.
  • Harbor Capital Advisors bought 329 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $21K.
  • Tarsus Pharmaceuticals made up 0.13% of Harbor Capital Advisors's portfolio in Q2 2026, its #241 holding.
  • Harbor Capital Advisors first reported a position in Tarsus Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
  • Harbor Capital Advisors's Tarsus Pharmaceuticals position peaked at $2.05M in Q1 2026.
  • 256 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Harbor Capital Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.